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ABSTRACT
This is a case study of a 15-year-old female who on chemotherapy and central line catheter-related bloodstream candidemia presented with recurrent 
episodes of candidemia, was febrile and breathless. She was diagnosed of Candida haemulonii fungemia. Echinocandins was started as this species of 
Candida is usually resistant to the commonly used antifungal agents. On treatment, the patient was afebrile and discharged.
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INTRODUCTION
Candidemia is one of the frequently seen blood stream infections. 
Candida haemulonii, one of the non-albicans Candida species, is known 
to be resistant to amphotericin B and azoles [1]. It is an emerging 
yeast pathogen involved in human infections such as onychia, ulcers 
of the feet or legs, and candidemia [2]. The treatment regimen for 
invasive C. haemulonii infections has not been clearly established. We 
investigated a case of febrile neutropenia catheter-related blood stream 
infection with recurrent episodes of candidemia due to C. haemulonii.
CASE REPORT
A 15-year-old female, a known case of osteosarcoma, was admitted 
for chemotherapy on June 3, 2015, in the department of pediatric 
oncology and had undergone left limb salvage surgery in the past. In the 
following 5th day of chemotherapy, she had dehydration, so intravenous 
fluids were administered, and the very next day, fever spikes were seen. 
Blood culture report revealed no growth. She was discharged on June 
30, 2015.
The patient was readmitted on July 13, 2015 for chemotherapy, and on 
the 3rd day, the patient showed dehydration and central line catheter 
was inserted. On July 23, 2015, the patient showed visible symptoms 
of fever, cold, cough, chest pain, palpitations, and breathlessness. Blood 
culture and Gram stain revealed Candida, hence azoles were started. 
The final blood culture report revealed C. haemulonii and second blood 
culture report revealed Candida parapsilosis. Central line catheter was 
removed immediately. This case revealed febrile neutropenia catheter-
related blood stream infection due to recurrent episodes of candidemia. 
As azoles and amphotericin B were found to be resistant in most of the 
C. haemulonii infections, micafungin belonging to echinocandins and 
flucytosine being nucleoside analog was given for 10 days and the 
patient was afebrile on June 30, 2015. On August 17, 2015, chemo port 
was removed and she was discharged.
The patient’s consent and Institutional Ethical Committee clearance 
were obtained. Blood cultures were routinely collected in aerobic 
media and incubated using the BacT/ALERT system (bioMerieux, USA). 
Cultures with a positive signal in the microbial automated detection 
system (i.e., alarm-positive cultures) were subcultured by standard 
methods onto blood agar, chocolate agar, and MacConkey’s medium, and 
aliquot was taken from positive bottles for Gram stain. Identification 
and antimicrobial susceptibility testing of the isolates to antimicrobial 
agents was performed using the VITEK2 system, bioMerieux, France. 
The presumptive identification of Candida isolates was done by 
conventional methods such as colony morphology showing white-to-
cream-colored pasty colonies, Gram staining from the colony showed 
Gram-positive budding yeast cells with or without pseudohyphae, 
germ tube test being negative, and HICHROME differential medium. 
The former sample was identified as C. haemulonii after 19 hrs of 
incubation with resistance to amphotericin B with minimum inhibitory 
concentration (MIC) ≥16 and azoles such as fluconazole with MIC 
≥64 and voriconazole with MIC ≥8 and sensitive to echinocandins 
such as caspofungin with MIC=0.5, micafungin with MIC=0.25, and 
flucytosine MIC=64. The latter sample was identified as C. parapsilosis 
after 31 hrs of incubation and was sensitive to all the antifungal drugs, 
i.e., amphotericin B with MIC=0.5, fluconazole with MIC ≤1, voriconazole 
with MIC ≤1, flucytosine with MIC ≤1, and caspofungin and micafungin 
with MIC=0.5.
A study was done to check the biofilm production by crystal violet assay 
and antifungal susceptibility for azoles by Kirby–Bauer’s method. It was 
performed on Mueller–Hinton agar supplemented with 2% glucose and 
0.5 µg/ml of methylene blue for enhancing the definition of growth 
margins [3]. C. parapsilosis showed weak adherence and was sensitive 
to both the antifungal agents (20 mm) while C. haemulonii revealed 
strong biofilm production and was resistance to fluconazole (zone 
diameter=6 mm) and sensitive to voriconazole (zone diameter =27 mm). 
When compared with VITEK MIC results, voriconazole with MIC ≥8 
was resistant which indicates very major error (VME), this is due to 
false-negative disk diffusion results and is usually seen in non-Candida 
albicans species [4]. In such cases, VITEK (MIC) results should be 
considered (MIC interpretive criteria for voriconazole were those 
approved by the Clinical and Laboratory Standards Institute [CLSI] as 
follows: Susceptible, MIC of ≤1 µg/ml; susceptible dose dependent, 
MIC of 2 µg/ml; and resistant, MIC of ≥4 µg/ml. The interpretive 
criteria for the voriconazole disk diffusion method were those used 
by the CLSI [CLSI document M44-A, 2005], as follows: Susceptible, 
zone diameter of ≥17 mm; susceptible dose dependent, zone diameter 
of 14 to 16 mm; and resistant, zone diameter of ≤13 mm). MEs 
were classified as resistant by disk diffusion (participant or central 
laboratory) and susceptible by broth microdilution (BMD) or resistant 
by the participant disk diffusion test and susceptible by the central 
laboratory disk diffusion test. VMEs were classified as susceptible by 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i2.15775
Case Report
2
Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 1-2
 Sanyuktha et al. 
the participant or central laboratory disk diffusion test and resistant by 
BMD or susceptible by the participant disk diffusion test and resistant 
by the central laboratory disk diffusion test. MEs occurred when the 
result of one of the tests was susceptible or resistant and that of the 
other test was susceptible dose dependent [4].
DISCUSSION
Previous reports and our case show that C. haemulonii is susceptible 
to echinocandins such as caspofungin or micafungin [1] and is 
resistant to amphotericin B and fluconazole [1,2]. There are only few 
cases that reveal the eradication of C. haemulonii-related candidemia 
through echinocandins administration [1,5,6]. In some cases, the 
administration of azoles such as fluconazole has failed to eradicate 
candidemia [5,6]. Identical patterns of susceptibility, with borderline 
sensitivity to amphotericin B, dose-dependent sensitivity to 
fluconazole, and resistance to the echinocandins tested (micafungin) 
were seen in 3 cases [7]. VME is rare and if it occurs, it is usually seen in 
non-C. albicans species. Risk factors for candidemia are the use of central 
venous catheters, total parenteral nutrition, use of multiple antibiotics, 
previous steroid therapy, postsurgery, and an immunocompromised 
status [8,9]. In our case study, long-term central venous catheterization 
for hyperalimentation and chemotherapeutic agents was the associated 
risk factor and no other source of infection was obtained. In previous 
case reports, the majority of patients received an intravenous central 
line and were in an immunocompromised state [1].
CONCLUSION
C. haemulonii is considered to be an emerging yeast pathogen for which 
the approach of patient management has yet to be illuminated. This 
is the first case to be reported in Dakshina Kannada. Fluconazole and 
amphotericin B are not a drug of choice for the treatment of C. haemulonii 
candidemia. Echinocandins, such as caspofungin or micafungin, may 
be an appropriate empirical choice of antifungal agent for invasive 
C. haemulonii infections. This case illustrates the importance of correct 
identification of Candida species and the use of appropriate drug for 
the treatment.
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